Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema

References

• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26:307–317.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2014;15:961–977.
   PubMed Web of Science ®Google Scholar
• Gavaldà A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009;331:740–751.
   PubMed Web of Science ®Google Scholar
• Gavaldà A, Gabarda E, Milara J, et al. Pharmacological assessment of the in vitro functional selectivity of aclidinium bromide at M3 and M2 muscarinic receptors in human tissue. Pulm Ther. 2015;1:103–107.
   Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014;745:135–143.
   PubMed Web of Science ®Google Scholar
• Sentellas S, Ramos I, Albertí J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010;39:283–290.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Matera MG. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14:1205–1214.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383–390.
   PubMed Web of Science ®Google Scholar
• Santus R, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Kerwin E, Rennard S, et al. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD. 2013;10:500–510.
   PubMedGoogle Scholar
• Gelb AF, Tashkin DP, Make BJ, et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013;107:1957–1965.
   PubMed Web of Science ®Google Scholar
• Mróz RM, Ausin MP, Lamarca R, et al. Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: phase III data by GOLD 2013 classification [abstract]. Eur Respir J. 2014;44 Suppl 58:P891.
   Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.
   PubMed Web of Science ®Google Scholar
• Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD010509.
   Google Scholar
• Jones PW, Leidy NK, Hareendran A, et al. Aclidinium bromide improves COPD symptoms assessed using the EXAcerbations of chronic pulmonary disease tool-respiratory symptoms questionnaire: pooled analysis of two phase III studies [abstract]. Am J Respir Crit Care Med. 2015;191:A3971. (Meeting Abstracts)
   Google Scholar
• Beier J, Kirsten A-M, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. Copd. 2013;10:511–522.
   PubMedGoogle Scholar
• Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616–624.
   PubMed Web of Science ®Google Scholar
• McGarvey L, Morice A, Smith J, et al. The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: results from phase III studies [abstract]. Eur Respir J. 2014;44 Suppl 58:P920.
   Google Scholar
• Wedzicha JA, Donaldson G, Chuecos F, et al. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: pooled analysis of phase III studies [abstract]. Eur Respir J. 2014;44 Suppl 58:A1888.
   Google Scholar
• Oba Y, Lone NA. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015;9:3–15.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Med. 2014;14:209.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Beck E, Alcaide D, et al. Overall and cardiovascular safety of aclidinium bromide in patients with COPD: results of a pooled analysis [abstract]. Eur Respir J. 2014;44 Suppl 58:P893.
   Google Scholar
• Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010;31:321–333.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med. 2014;35:191–201.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10:110–120.
   Google Scholar
• Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD – a network meta-analysis. Respir Res. 2013;14:100.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–1103.
   PubMed Web of Science ®Google Scholar
• Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:11.
   PubMed Web of Science ®Google Scholar
• Wu K, Looby M, Pillai G, et al. Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn. 2011;38:105–119.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106:249–256.
   PubMed Web of Science ®Google Scholar
• Segreti A, Stirpe E, Rogliani P, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18:381–388.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Catalunā JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50(Suppl 1):1–16.
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest. 2011;140:626–633.
   PubMed Web of Science ®Google Scholar
• McKeage K. Tiotropium Respimat®: A review of its use in asthma poorly controlled with inhaled corticosteroids and long-acting β2-adrenergic agonists. Drugs. 2015;75:809–816.
   PubMed Web of Science ®Google Scholar
• Damera G, Jiang M, Zhao H, et al. Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol. 2010;649:349–353.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Ora J, et al. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med. 2015;109:1305–1311.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
   PubMed Web of Science ®Google Scholar